Search results for

Austria is one the countries which offers protection for technical inventions not only via patents but also utility models. When the Austrian legislator enacted the first Utility Model Act in 1994 he commented that the requirement of inventiveness for utility models was lower than that for patents.

Recently, the Australian courts found that use of a trade mark on a global website amounted to use in Australia. In International Hair Cosmetics Group Pty Ltd v International Hair Cosmetics Limited, the Australian Federal Court addressed the issue of whether use of a trade mark on a UK-based website that included Australia as one option in a drop-down box amounted to Australian use.

One of the fields where science has made the greatest progress in the past few decades is biotechnology, and it is precisely in the area of biotechnological patents, and especially those related to microorganisms, where the Argentine Republic faces one important challenge.

In Alliance Property Group v Alliance Group (March 14 2011), the South African Supreme Court of Appeal upheld an appeal from Alliance Property Group, ruling that Alliance Group Limited was passing its business off as being associated with that of Alliance Property Group.

Maastricht University is to host a roundtable discussion on IP rights, standards and innovation next month

At the end of the first quarter of 2011 there were more than 209.8 million domain name registrations, according to a report published by VeriSign

WIPO has written a letter to Icann advising it against revising the UDRP.

Icann’s Board has held discussions with the GAC ahead of the scheduled publication of the final Applicant Guidebook for gTLDs on Monday

The G8 meeting in Paris is expected to release a call today for tighter regulation of the internet, including stronger privacy rights and rules on copyright piracy

Covington & Burling has added four life sciences partners to its London office, from Morrison & Foerster. Paul Claydon, Natalie Diep, James Gubbins and James Halstead have all joined a team that is spread across London and Brussels in Europe. They advise life sciences, technology and renewable energy industry clients on mergers and acquisitions, IPOs and follow-on financings, and private equity and venture capital transactions. The team has worked together for many years, and was ranked first for number of UK pharmaceutical M&A deals for four years from 2007 to 2010. Notable transactions including advising Acambis on the £276 million recommended takeover offer from Sanofi-Aventis, IS Pharma on the recommended merger with Sinclair Pharma and Liberum Capital on the AIM IPO by HaloSource.